STERIS plc

During the three months ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted, modified orterminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as such terms are defined under Item 408 of Regulation S-K, except as follows:

On November 19, 2025, J. Adam Zangerle, Senior Vice President, General Counsel, and Company Secretary of the Company, adopted a trading arrangement for the sale of the Company’s ordinary shares that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act, as amended (the “Exchange Act” and such plan, a “Rule 10b5-1 Trading Plan”). Mr. Zangerle’s Rule 10b5-1 Trading Plan, which expires March 15, 2027, provides for the sale of up to 16,003 ordinary shares pursuant to the terms of such plan. The actual number of ordinary shares available to be sold under the Rule 10b5-1 Trading Plan for ordinary shares subject to unvested awards will be calculated at the time of vesting of such equity awards after withholding to satisfy tax obligations.